Brief: Contrafect Provides Update From The Futility Analysis Of The Phase 3 Disrupt Study Of Exebacase
19/12/2022 21:38
Dec 19 (Reuters) - ContraFect Corp CFRX.O :
* CONTRAFECT PROVIDES UPDATE FROM THE FUTILITY ANALYSIS OF
THE
PHASE 3 DISRUPT STUDY OF EXEBACASE
* CONTRAFECT CORP - REMAIN ON TRACK TO INITIATE A PHASE 1
STUDY
OF CF-370 IN Q2 OF 2023
* CONTRAFECT CORP - FULL RESULTS AND PHASE 3 DISRUPT STUDY
REPORT
ARE EXPECTED IN Q1 OF 2023
Source text for Eikon: ID:nGNX5PMYN3
Further company coverage: CFRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CONTRAFECT
See all newsBrief: Contrafect Corp - On Nov 7, Co Received Delisting Notification From Nasdaq Hearings Advisor Stating That Panel Determined To Delist Co's Common Stock
Brief: ContraFect Says Selling Securityholder May Offer And Selling Up To 7 Mln Shares In Aggregate Of Common Stock
Brief: Contrafect Announces FDA Clearance Of CF-370 IND Application To Proceed With Phase 1 Clinical Study
Brief: Contrafect Corp Says On Sept 21, Notified By Nasdaq, That Co Not In Compliance With The Minimum Bid Price Requirement
Brief: Contrafect Announces Submission Of Ind Application To The FDA For Its Development Candidate Cf-370